AccuMetab™ Pig CYP3A39 Enzyme, Catalytically Active

CAT#: ITS-0426-YL54
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Pig CYP3A39 for reliable preclinical Phase I ADME profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Analogous to human CYP3A4, pig CYP3A39 is the dominant Phase I enzyme in the porcine liver and intestine. It is a strictly required assay model for researchers developing oral therapeutics intended to be tested in large animal GI and first-pass metabolism models.
Key Features
Dominant porcine hepatic and GI enzyme; Required for swine oral bioavailability scaling; Pre-coupled with pig NADPH reductase; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Preclinical Species Comparison
Research Areas
ADME; Preclinical Toxicology
Species
Pig
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
1 nmol
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry